Chymal Therapeutics

Chymal Therapeutics Inc. is a pioneering biotechnology startup focused on developing next-generation cellular therapies to address autoimmune and degenerative diseases. The company is advancing a proprietary platform of chimeric antigen receptor mesenchymal stromal cells (CAR-MSCs) with a novel mechanism of action for superior immunomodulatory efficacy. Chymal Therapeutics aims to transform the treatment landscape for autoimmune disorders by creating scalable, off-the-shelf CAR-MSC therapies with enhanced precision and efficacy. The core innovation lies in Chymal’s CAR-MSC platform, which combines mesenchymal stromal cells with chimeric antigen receptors. CAR-MSCs address significant challenges in the treatment of autoimmune disorders. While MSCs have demonstrated immunosuppressive capabilities, their standalone therapeutic efficacy has been limited due to challenges in homing to inflamed tissues and sustaining targeted action. By engineering MSCs with CARs, this novel approach boosts their precision and therapeutic potency, enabling them to: 1. Precisely target disease sites: CAR-MSCs are programmed to attach to specific markers on diseased or inflamed cells. 2. Suppress immune hyperactivity: They modulate the immune system, preventing it from attacking the body’s own tissues. 3. Enhance healing outcomes: CAR-MSCs release proteins that facilitate tissue repair and control chronic inflammation. The lead candidate, CHY-001, is designed to target E-cadherin—a critical protein expressed in damaged epithelial tissues in acute GvHD and other inflammatory diseases. CHY-001 will provide a first-in-class therapeutic solution for steroid-refractory acute GvHD, with potential expansion into indications such as Crohn’s disease and ulcerative colitis.